You’re using a public version of DrugPatentWatch with 5 free searches available | Register to unlock more free searches. CREATE FREE ACCOUNT

Last Updated: May 23, 2024

~ Buy the NEURACEQ (florbetaben f-18) Drug Profile, 2024 PDF Report in the Report Store ~

CLINICAL TRIALS PROFILE FOR NEURACEQ


✉ Email this page to a colleague

« Back to Dashboard


All Clinical Trials for Neuraceq

Trial ID Title Status Sponsor Phase Start Date Summary
NCT02831283 ↗ Imaging Inflammation in Alzheimer's Disease Enrolling by invitation National Institute on Aging (NIA) Phase 2 2016-06-01 This study is being done to learn about inflammation and amyloid in Alzheimer's disease. A type of brain scan called a PET scan is used measure 1) inflammation and 2) abnormal accumulation of a the amount of a certain protein fragment called beta-amyloid (plaques) in the brain. These are thought to be involved in Alzheimer's disease. The investigators will also perform brain MRI and do tests to measure the participants' memory and thinking.
NCT02831283 ↗ Imaging Inflammation in Alzheimer's Disease Enrolling by invitation William Charles Kreisl Phase 2 2016-06-01 This study is being done to learn about inflammation and amyloid in Alzheimer's disease. A type of brain scan called a PET scan is used measure 1) inflammation and 2) abnormal accumulation of a the amount of a certain protein fragment called beta-amyloid (plaques) in the brain. These are thought to be involved in Alzheimer's disease. The investigators will also perform brain MRI and do tests to measure the participants' memory and thinking.
NCT03119558 ↗ PET/MRI Evaluation of Cardiac Amyloid Completed Stanford University Early Phase 1 2016-05-26 Cardiac amyloidosis is a disorder characterized by the deposition of abnormal proteins called amyloid in the heart tissue. This makes it difficult for the heart to function properly. The investigators wish to evaluate if the radiopharmaceutical 18F-Florbetaben (Neuraceq®) that targets beta amyloid can also identify cardiac amyloid deposition.
NCT03744312 ↗ Imaging Inflammation in Alzheimer's Disease With 11C-ER176 Enrolling by invitation William Charles Kreisl Phase 1/Phase 2 2018-09-10 This study is being done to learn about inflammation in the brain of those with Alzheimer's disease (AD). The purpose of this study is to determine if 11C-ER176 is able to accurately measure inflammation in patients with Alzheimer's disease. Both patients (with either mild cognitive impairment (MCI) or Alzheimer's disease) and healthy controls (participants without memory complaints or impairment) will be included in this study.
>Trial ID >Title >Status >Phase >Start Date >Summary

Clinical Trial Conditions for Neuraceq

Condition Name

Condition Name for Neuraceq
Intervention Trials
Alzheimer Disease 2
Cardiac Amyloidosis 2
AL Amyloidosis 1
Alzheimer's Disease 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Condition MeSH

Condition MeSH for Neuraceq
Intervention Trials
Alzheimer Disease 3
Amyloidosis 3
Inflammation 2
Immunoglobulin Light-chain Amyloidosis 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Locations for Neuraceq

Trials by Country

Trials by Country for Neuraceq
Location Trials
United States 4
Korea, Republic of 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Trials by US State

Trials by US State for Neuraceq
Location Trials
New York 3
California 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Progress for Neuraceq

Clinical Trial Phase

Clinical Trial Phase for Neuraceq
Clinical Trial Phase Trials
Phase 3 1
Phase 2 2
Phase 1/Phase 2 1
[disabled in preview] 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Status

Clinical Trial Status for Neuraceq
Clinical Trial Phase Trials
Completed 2
Enrolling by invitation 2
Not yet recruiting 1
[disabled in preview] 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Sponsors for Neuraceq

Sponsor Name

Sponsor Name for Neuraceq
Sponsor Trials
William Charles Kreisl 3
National Institute on Aging (NIA) 2
Stanford University 1
[disabled in preview] 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Sponsor Type

Sponsor Type for Neuraceq
Sponsor Trials
Other 5
NIH 2
Industry 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.